Axsome Therapeutics, Inc. AXSM

Axsome Therapeutics announced results from the Shared Goals: Navigating Alzheimer's Agitation survey, presented at Psych Congress 2026 in connection with World Alzheimer's Day. The Harris Poll survey of 751 informal caregivers found agitation in Alzheimer's disease is often not recognized until daily life is severely disrupted. Caregivers reported 97% of patients’ agitation hurting overall quality of life, 96% self-care, 95% community engagement, and 89% relationships. While 85% are involved in treatment decisions, 76% wished symptoms had been recognized earlier and 53% regret not discussing agitation with the patient’s clinician sooner. Nonaggressive agitation symptoms—like complaining, negativism, repetitive questions, and pacing—were most detrimental. Caregivers want tools to track symptoms (89%) and share data with doctors (81%), and 93% wish for a medication that reduces agitation without negative side effects. Axsome sponsored the survey; results were presented Sept 17–18, 2026. Shows substantial caregiver burden and a clear market need for safer agitation treatments, with Axsome's sponsorship signaling potential upside for its CNS portfolio, yielding a moderate impact.

Axsome Therapeutics reports accelerating AUVELITY prescriptions as its Alzheimer’s launch gains traction. Accelerating prescriptions and Alzheimer’s launch traction signal strong commercial momentum for Axsome.

Axsome Therapeutics released new central nervous system data to support its neuropsychiatric portfolio, with questions raised on whether the results sufficiently strengthen the company's overall story. New CNS clinical data directly affects Axsome's product pipeline and could materially shift its market position and investor sentiment in neuropsychiatry.

Axsome Therapeutics reported new clinical data on treatments for depression and Alzheimer’s agitation. New clinical data in core CNS indications can drive pipeline advancement and valuation shifts for Axsome.

Axsome Therapeutics highlighted continued Auvelity sales growth and pipeline advancements at the H.C. Wainwright Global Investment Conference. Conference updates on Auvelity growth and pipeline progress may lift near-term sentiment but lack major regulatory or launch events.

AXSM shares rose 6% after Mizuho labeled Auvelity’s Alzheimer’s launch a strong start. Mizuho positive commentary on Auvelity launch points to moderate revenue upside and positioning gains.

Axsome Therapeutics initiates Phase III clinical study of AXS-05 for smoking cessation. Phase III start for AXS-05 in smoking cessation expands pipeline and may lift sentiment yet remains pre-approval with no near-term revenue impact.

Axsome Therapeutics, Inc. (AXSM) initiates the SUMMIT Phase 3 Trial of AXS-05 in smoking cessation. Phase 3 trial start expands AXS-05 pipeline into smoking cessation and may influence near-term development progress.

Axsome Therapeutics stock rose 16% year to date with Wall Street analysts projecting additional upside from upcoming company catalysts. Analyst views on further stock gains can lift near-term sentiment and trading without altering core operations.

Axsome Therapeutics reported Q2 earnings matching estimates with Auvelity driving year-over-year revenue growth. Meeting estimates with Auvelity-led revenue growth signals moderate positive effects on financial trajectory.

Axsome Therapeutics CEO claims one new drug filing yearly through 2030, advancing AXSM stock. Long-term pipeline commitment of annual filings signals major strategic expansion likely to reshape growth trajectory.

Axsome Therapeutics reported Q2 earnings with analysis of key financial metrics. Quarterly earnings metrics can shift near-term investor sentiment on financial results.

Axsome Therapeutics Q2 earnings call covered financial results, pipeline progress on CNS treatments, revenue updates and outlook for upcoming regulatory milestones. Q2 earnings call supplies financial metrics and pipeline status that moderately shape near-term investor sentiment and valuation.

Axsome Therapeutics reported a Q2 loss and missed revenue estimates. Q2 earnings miss may pressure near-term stock price and sentiment.

Analysts forecast Axsome Therapeutics (AXSM) will report lower earnings. Earnings decline estimates may pressure AXSM stock and near-term sentiment.

Axsome Therapeutics (AXSM) stock appears attractive due to strength of its key drug. Positive outlook tied to key drug implies major influence on company trajectory and investor views.

Jazz Pharmaceuticals refocuses its sleep franchise while analysts question whether the stock remains undervalued amid shifting priorities and competitive pressures in narcolepsy and related markets. Jazz's sleep franchise adjustments alter competitive dynamics for Axsome's pipeline assets in overlapping indications.

FDA accepts Axsome Therapeutics NDA for AXS-12 in narcolepsy. NDA acceptance moves AXS-12 toward potential approval and directly lifts company trajectory.

FDA accepts Axsome Therapeutics' New Drug Application for AXS-12 to treat cataplexy in narcolepsy. NDA acceptance for AXS-12 marks key regulatory progress toward potential approval and revenue.

Axsome Therapeutics advances Solriamfetol into Phase 3 pediatric ADHD trials. Phase 3 initiation expands Solriamfetol addressable market into pediatric ADHD and can materially shift revenue outlook.

Axsome Therapeutics advances FOCUS 2 dosing in ADHD program as market assesses whether potential upside is already reflected in AXSM shares. ADHD trial progress offers moderate pipeline visibility without new pivotal data or approvals.

Axsome Therapeutics initiates Phase III trial of Solriamfetol for ADHD treatment in children. Phase III start for new pediatric ADHD indication advances pipeline and expands future revenue potential.

Axsome Therapeutics initiates FOCUS-2 Phase 3 trial of Solriamfetol in children with ADHD. Phase 3 initiation expands Solriamfetol into large pediatric ADHD market with major revenue potential.

Axsome Therapeutics initiates FOCUS-3 Phase 3 trial of solriamfetol in adolescents with ADHD. Phase 3 trial start expands solriamfetol pipeline into adolescent ADHD with moderate long-term revenue impact.

Axsome Therapeutics presented new data highlighting its innovative sleep medicine portfolio at SLEEP 2026. Conference data presentation on sleep portfolio advances product visibility and innovation perception with moderate influence on future trajectory.

Axsome Therapeutics prepares Auvelity launch for Alzheimer’s agitation treatment while expanding its central nervous system pipeline. Auvelity launch in new indication plus pipeline expansion represent major strategic moves with potential to significantly boost revenue and market position.

Patent peace on SUNOSI and new migraine data prompt reevaluation of Axsome Therapeutics bull case. SUNOSI patent settlement plus migraine data may shift company trajectory and sentiment but effects remain balanced by other factors.

Axsome Therapeutics presented new SYMBRAVO data at the American Headache Society 68th Annual Scientific Meeting. Conference data release on SYMBRAVO can lift visibility and short-term sentiment without shifting long-term trajectory.

Axsome Therapeutics settled all patent litigation over SUNOSI (solriamfetol), ending disputes and securing resolution on the drug's intellectual property rights. Settlement removes litigation risks around SUNOSI and supports ongoing commercialization without altering core company trajectory.

Axsome Therapeutics presented new AUVELITY data in major depressive disorder at the American Society of Clinical Psychopharmacology 2026 Annual Meeting. New clinical data presentation for lead product may moderately shift investor views on efficacy without changing operations or approvals.